If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more. Nuclear medicine plays a very important role in the ...

The IAEA has recently launched SAFRON for Radionuclide Therapy, an incident learning system to help medical facilities improve safety of patients and staff. The objective of this new learning system ...

Alfa Cytology offers specialized radiolabeling and antibody-radionuclide conjugate development to advance radiopharmaceutical ...

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant ...

Combination of alpha- and beta-radionuclide therapy is feasible, tolerable, and effective for colorectal cancer, according to preclinical research presented at the 2024 Society of Nuclear Medicine and ...

After the Fukushima nuclear power plant accident, managing environmental radionuclide contamination efficiently has become incredibly important. In light of this, a team of scientists have provided ...

Radionuclide therapy is an increasingly important modality in the treatment of various malignancies, utilising radiopharmaceuticals to deliver targeted cytotoxic radiation to diseased tissues. Central ...

Prostate cancer is the most common cancer in men and at later stages of the disease many patients develop painful bone metastases. One promising modality for management of skeletal metastases is ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...

Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4%. It is typically a silent malignancy ...